WGS Share Price Performance
US$66.20
-18.57 (-21.91%)
49.1% undervalued intrinsic discount
US$130.00
Fair Value
Price US$66.20
AnalystLowTarget US$130.00
AnalystConsensusTarget US$156.67
AnalystHighTarget US$156.97
Fair ValueUS$130.00
Share Pricen/a
GeneDx Holdings Corp. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 57 Fair Values set on narratives written by author
WGS Community Narratives
AN
Fair Value US$130 49.1% undervalued intrinsic discount
Government Cost-Containment And Tightening Privacy Laws Will Squeeze Margins
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$156.67 57.7% undervalued intrinsic discount
WGS: Customer Conversion And Market Expansion Will Shape Rare Disease Diagnostics
0users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
AN
Fair Value US$156.97 57.8% undervalued intrinsic discount
Genomics And AI Integration Will Expand Precision Healthcare Adoption
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Government Cost-Containment And Tightening Privacy Laws Will Squeeze Margins
Key Takeaways Rising regulatory and reimbursement pressures threaten to squeeze margins and limit GeneDx's ability to capitalize on its genomic database. Intensifying industry competition and slow clinical adoption risk eroding market share and dampening growth prospects.Read more
37
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$130
49.1% undervalued intrinsic discount
Fair Value
Profit Margin
2.13%
Future PE
297.79x
Price in 2029
US$155.75
WGS: Customer Conversion And Market Expansion Will Shape Rare Disease Diagnostics
Key Takeaways Accelerating adoption of genomics in pediatrics and enhanced AI platforms drive growth, efficiency, and margin improvement while reinforcing competitive advantage. Increasing reimbursement, enriched rare disease datasets, and global biopharma partnerships support recurring revenues, premium pricing, and high barriers to entry.Read more
289
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
AN
US$156.67
57.7% undervalued intrinsic discount
Fair Value
Profit Margin
7%
Future PE
101.47x
Price in 2029
US$187.7
Genomics And AI Integration Will Expand Precision Healthcare Adoption
Key Takeaways Exclusive data, AI platform, and strategic integration efforts position GeneDx for sustained market leadership, margin expansion, and outperformance relative to analyst expectations. Shifts in testing guidelines and biopharma partnerships will catalyze broad adoption, recurring high-margin revenues, and accelerating competitive advantage through network effects.Read more
25
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$156.97
57.8% undervalued intrinsic discount
Fair Value
Revenue
23.89% p.a.
Profit Margin
18.84%
Future PE
47.11x
Price in 2028
US$186.17
Trending Discussion
Recently Updated Narratives
AN
WGS: Prenatal Focus And Coverage Gains Will Reshape Prospects For This Undervalued Leader
Fair Value: US$130 49.1% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
WGS: Prenatal Anomaly Sequencing Will Drive Future Confidence And Repricing
Fair Value: US$156.67 57.7% undervalued intrinsic discount
27 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Genomics And AI Integration Will Expand Precision Healthcare Adoption
Fair Value: US$156.97 57.8% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
GeneDx Holdings Corp. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.72
- 69.74%
- -4.92%
- 17.1%
About WGS
- Founded
- 2000
- Employees
- 1300
- CEO
- WebsiteView website
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
